Pharmasset's Underwriters Release Shares fr...( PRINCETON N.J. Oct. 16 /- Pharmas...),Health
Navigation Links
Pharmasset's Underwriters Release Shares from Lock-Up
Date:10/16/2007
PRINCETON, N.J., Oct. 16 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today the early termination by its Underwriters of the lock-up letter agreements that were executed in conjunction with the initial public offering of Pharmasset's common stock. The termination of transfer and sale restrictions set forth in the agreements will be effective on October 19, 2007. The lock-up agreements cover an aggregate of approximately 16 million shares of Pharmasset common stock.
Upon the termination of the lock-up agreements, these shares will be available for sale subject to any resale restrictions of the federal securities laws, including, in some instances, the limitations of Rule 144 or 701 under the Securities Act of 1933, as amended. Pharmasset completed its initial public offering of 5,000,000 shares of common stock on May 2, 2007 at a public offering price of $9.00 per share.
About Pharmasset
Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).
Pharmasset is currently developing three product candidates. Clevudine,
for the treatment of chronic HBV infection, is in Phase 3 clinical trials
for registration in the Americas and Europe. Clevudine is already approved
for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South
Korea under the brand name Levovir. R7128, an oral treatment for chronic
HCV infection, is in a 28-day Phase 1 clinical trial in combination with
Pegasys(R) and Copegus(R) throu
'/>"/>
| SOURCE Pharmasset, Inc. Copyright©2007 PR Newswire. All rights reserved |
Related medicine news :
1. Sweet corn releases antioxidants on cooking
2. Stents That Release Medication To Check Artery Narrowing
3. NABH Health accreditations final draft to be released by this month
4. Students Seek Help From Prisoners for Kidnapped Childs Release
5. Indian National in Saudi Jail will be released soon
6. Single Dose Of Extended Release Metformin Found To Be Effective In Type 2 Diabetes
7. An International Growth Standard For Childs Releases By WHO
8. Infection-Induced Amputation On Diabetic Foot – Study Release
9. New Guidelines Released for Patients Suffering from Heart Disease
10. AIIMS medical Superintendent confirms that salary release has not been permitted
11. Controversy Over Release Of Salaries Of Striking AIIMS Doctors
Post Your Comments:
(Date:10/6/2008)...ospital Ship Serving in West Africa Receives Acces...ley, Texas October 6, 2008 -- www.seamobile.com [S... of communications services to remote locations, a...oxNews channel via satellite to Mercy Ships onboar... The Africa Mercy is the world,s largest non-gove...
(Date:10/5/2008)...iderable disparities in survival related to race a...and neck cancer. Published in the November 15, 200...e American Cancer Society, the study indicates tha...t could improve outcomes for these cancers among A...dies have examined disparities in cancer survival ...
(Date:10/5/2008)...ifficult to kill a spider as it scurries across th...er set foot on a plane. While nothing physically ...r can keep them from the task at hand. , The sam...hysical activity, according to research presented ... , Researchers from the Center for Obesity Resea...
(Date:10/3/2008)...ide Komen Community Challenge Campaign to Close,th...come Women and Women of ... Pennsylvania House Speaker Dennis,O,Brien (R-169t... survivors,and advocates from the Philadelphia Aff...ic forum this morning to call for policies to clos...
Breaking Medicine News(10 mins):Health News:Seamobile Provides Foxnews To Mercy Ships 2Health News:Seamobile Provides Foxnews To Mercy Ships 3Health News:News from Cancer: Disparities in head and neck cancer patients 2Health News:Mental barriers hamper obese women's efforts to get exercise 2Health News:Susan G. Komen for the Cure(R), Speaker Dennis O'Brien, Obama and McCain Health Care Advisors, Breast Cancer Survivors and Advocates Call for Needed Health Care Reforms 2Health News:Susan G. Komen for the Cure(R), Speaker Dennis O'Brien, Obama and McCain Health Care Advisors, Breast Cancer Survivors and Advocates Call for Needed Health Care Reforms 3[0] Seamobile Provides Foxnews To Mercy Ships [1] News from Cancer: Disparities in head and neck cancer patients[0] Mental barriers hamper obese women's efforts to get exercise[1] Susan G. Komen for the Cure(R), Speaker Dennis O'Brien, Obama and McCain Health Care Advisors, Breast Cancer Survivors and Advocates Call for Needed Health Care Reforms
...cably at an average age of 14, conventional autops...researchers conducted a// sophisticated form of po...utopsy -- they found that more than one-third died... defects that impair the heart’s rhythm center. T...
...leased by the Health Protection Agency (HPA) of Br... cases of infection by bugs including the potentia... the ‘super bug’ MRSA. According to the released ...tridium infections have risen drastically by 5.5 p...
...ncy Services (TCS) Tuesday announced a $6 million ...ay Hospitals to provide and implement a healthcare...e deal, TCS will work with Parkway Hospitals to cu...ement Solution (HMS) as per its specific needs, a ...
...umans to treat obesity from a drug derived from th...over, the Managing Director of the company. As pe...in Cannabis plant and each part of the plant has a... part of the cannabis plant has the power to curb ...
Other Medicine News:Health News:Young People Who Died Suddenly, Inexplicably Had Genetic Heart Defects 2Health News:Young People Who Died Suddenly, Inexplicably Had Genetic Heart Defects 3Health News:Lethal Hospital Bug Tough to Knock Down, Statistics Reveal 2(Date:10/6/2008)...ntific Conference -, ORLANDO, Fla., Oct. 6 /PRNew...bia) today announced presentation of data from a p...at cyclic guanosine,monophosphate (cGMP) plays in ...rate that cGMP inhibits intestinal pain in a precl...itizes colonic afferent nerves in a,similar model ...
(Date:10/6/2008)...py is More Likely to Induce Steroid-Free Remissi... Immunomodulator, Azathioprine, OR... for the first time,from the Phase 3b Study of Pat...rs and Biologic Therapy (SONIC) may provide new in...moderate to severe Crohn,s disease.,According to f...
(Date:10/6/2008)...Naltrexone SR Associated with Bette.... 6 /- Orexigen Therapeutic...any focused on the treatment of,obesity and other ...esented,data showing the investigational drug, Con...lly achieved key objectives (lowered naltrexone,Cm...
(Date:10/5/2008)...f Medicine reaffirm,well-established efficacy and ...R), RIDGEFIELD, Conn., and NEW YORK, Oct. 5 /PRNe...tential Long-term Impacts on Function with,Tiotrop...tiotropium bromide,inhalation powder), sustained i...measured by FEV(1) (p<0.001) versus placebo in Chr...
Breaking Medicine Technology:Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 2Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 3New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 2New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 3New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 4New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 5New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 6New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 7New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 8Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 2Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 3Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 4Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 5Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 2Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 3Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 4Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 5Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 6Delivering Molecular Imaging Solutions Across Clinical Specialties 3A Siemens Showcases New Technologies at RSNA 2007 1871 1Delivering Molecular Imaging Solutions Across Clinical Specialties 3A Siemens Showcases New Technologies at RSNA 2007 1871 2Delivering Molecular Imaging Solutions Across Clinical Specialties 3A Siemens Showcases New Technologies at RSNA 2007 1871 3Delivering Molecular Imaging Solutions Across Clinical Specialties 3A Siemens Showcases New Technologies at RSNA 2007 1871 4Delivering Molecular Imaging Solutions Across Clinical Specialties 3A Siemens Showcases New Technologies at RSNA 2007 1871 5Regular exercise reduces risk of blood clots 6712 1Evolutionary comparison finds new human genes 1289 1Evolutionary comparison finds new human genes 1289 2Evolutionary comparison finds new human genes 1289 3New book presents methods to poke and prod individual molecules 1284 1New book presents methods to poke and prod individual molecules 1284 2[0] Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain[0] New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study[0] Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)[0] Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years
...07 - ImClone Systems,Incorporated (NASDAQ: IMCL) a...ced today that a first line Phase III study of,ERB...hemotherapy,met the primary endpoint of increasing...r metastatic squamous cell carcinoma of the,head a...y, known as,EXTREME, studied more than 400 patient...
...ESS WIRE)--Apr 3, 2007 -,Icagen, Inc. (NASDAQ: ICG...g of the independent Data Monitoring Committee,("D...ormerly,ICA-17043) for the treatment of sickle cel...trial be terminated because of the low,probability...ary,endpoint. In making their recommendation, the ...
Other Medicine Technology:Survival Data Available from Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 2Survival Data Available from Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 3Survival Data Available from Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 4Survival Data Available from Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 5Survival Data Available from Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 6Survival Data Available from Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 7Survival Data Available from Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 8Icagen Terminates Phase III ASSERT Study 2Icagen Terminates Phase III ASSERT Study 3...rt SI inserter from Bausch & Lomb provides fingert...ned for one handed delivery of the IOL directly in...assured by planar delivery. Leading haptic is posi...bag without sweeping motion. No additional instrum...
...erex Ultra Q is the fundamental capsulotmy laser -...ergy delivery and provides 2855% less energy in ai... in contemporary systems. This technology elimina...educes the risk of IOL pitting. , , , Ultr...
Protects the eye during or after surgery or trauma. Clear window dressing. Protects the eye allowing the patient to see.
Product designed specifically for posteror segment surgical procedures. For dissection of vitreoretinal membrames using viscoelastic fluid. A high pressure luer lock tubing set is attached to cannula
Medicine Products:| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |